SueWallSt

SueWallSt

By SueWallStBusinessInvesting
Download on the App Store

SueWallSt episodes

  • #071 $TLX in Hot Water Telix Faces SEC Heat Over Drug Development Disclosures

    Telix Pharmaceuticals $TLX is facing a federal subpoena and a scorching class action lawsuit after allegedly misleading investors about its prostate cancer drug pipeline and FDA compliance. In this episode of Sue Wall Street, we dive into how missing trial data, shady supply chain claims, and a bombshell FDA rejection sent the stock tumbling. Ideal for biotech investors, legal watchers, and anyone tracking pharmaceutical accountability. Get the facts, not just the filings.

    Visit ZLK.com for more info.

    Add our WhatsApp Channel.


    We’re not lawyers or accountants, so don’t take this as legal or financial advice.

    8 min
  • #070 $PRMB’s Merger Meltdown From “Flawless” to a $2 Billion Blowup

    Primo Brands $PRMB told investors their mega-merger was going “flawlessly” but behind the scenes, tech failures, service chaos, and internal breakdowns were flooding the company. In this episode of Sue Wall Street, we unpack how confident corporate spin turned into a shareholder disaster and triggered a class action lawsuit after a stunning 36% stock drop. If you follow M&A hype, beverage brands, or securities fraud cases, this one’s for you.

    Visit ZLK.com for more info.

    Add our WhatsApp Channel.


    We’re not lawyers or accountants, so don’t take this as legal or financial advice.

    8 min
  • #069 $LRN’s Ghost Students The EdTech Scandal That Rocked Wall Street

    Online learning giant Stride Inc $LRN is under fire for allegedly inflating enrollment with “ghost students” to boost funding triggering a massive stock crash and a class action lawsuit. In this episode of Sue Wall Street, we dive into whistleblower claims, fake student rosters, overworked teachers, and missed special ed services. Perfect for investors, educators, and anyone tracking EdTech accountability. Expect shocking details, legal breakdowns, and stock fallout.

    Visit ZLK.com for more info.

    Add our WhatsApp Channel.


    We’re not lawyers or accountants, so don’t take this as legal or financial advice.

    8 min
  • #068 $FLY and Fall Firefly’s IPO Burns Investors in Rocket Lawsuit

    Firefly Aerospace $FLY promised liftoff but shareholders got a crash landing. In this episode of Sue Wall Street, we break down how failed rocket launches, FAA groundings, and misleading IPO statements led to a fiery class action lawsuit. If you're into space stocks, IPO hype, or financial accountability, this is your orbit. Expect sharp analysis, timeline breakdowns, and insider commentary.

    Visit ZLK.com for more info.

    Add our WhatsApp Channel.


    We’re not lawyers or accountants, so don’t take this as legal or financial advice.

    8 min
  • #067 $FCX Under Fire The Mudslide That Sparked a Shareholder Showdown

    A deadly mud rush at Freeport-McMoRan’s $FCX Grasberg mine in Indonesia has triggered more than tragedy it’s now the center of a major class action lawsuit. In this gripping episode of Sue Wall Street, we break down how safety failures, misleading disclosures, and a steep stock plunge are fueling investor outrage. If you're into mining stocks, ESG accountability, or securities law drama, this one’s for you. Expect expert analysis, real talk, and financial firepower.

    Visit ZLK.com for more info.

    Add our WhatsApp Channel.


    We’re not lawyers or accountants, so don’t take this as legal or financial advice.

    8 min
  • #066 Molina’s $MOH Meltdown Two Guidance Cuts One Lawsuit

    Molina Healthcare $MOH stunned investors by slashing earnings forecasts—twice—in just two weeks, triggering a stock freefall and a major class action lawsuit. This episode of Sue Wall Street dives into how inflated guidance, hidden medical cost spikes, and shocking disclosures led to shareholder chaos. Perfect for investors, finance nerds, and corporate accountability watchdogs. Expect sharp commentary, deep dives, and eye-popping numbers.

    Visit ZLK.com for more info.

    Add our WhatsApp Channel.


    We’re not lawyers or accountants, so don’t take this as legal or financial advice.

    8 min
  • #065 $AVTR Meltdown Avantor’s Lab-Grade Confidence Evaporates in Court

    In this episode, we break down the class action lawsuit against Avantor $AVTR after the life sciences giant allegedly misled investors while bleeding accounts, slashing guidance, and posting a massive $785M goodwill impairment. From rosy earnings calls to brutal stock drops, we reveal how investor trust evaporated. Perfect for biotech watchers, institutional investors, and Wall Street skeptics. Get legal insights, sharp commentary, and real accountability.

    Visit ZLK.com for more info.

    Add our WhatsApp Channel.

    We’re not lawyers or accountants, so don’t take this as legal or financial advice.

    8 min
  • #064 $DXCM Drops the Ball DexCom’s Sensor Scandal Shocks Investors

    This episode exposes the class action lawsuit against DexCom $DXCM after unauthorized changes to its G6 and G7 glucose sensors sparked FDA warnings, tragic outcomes, and a brutal stock plunge. We break down how misleading safety claims and insider stock sales may have violated securities laws. Ideal for medtech investors, financial sleuths, and patient advocates. Expect sharp takes, real cases, and deep accountability.

    Visit ZLK.com for more info.

    Add our WhatsApp Channel.

    We’re not lawyers or accountants, so don’t take this as legal or financial advice.

    8 min
  • #063 $INSP Implodes The Sleep Apnea Launch That Put Investors to Bed

    We uncover the class action lawsuit against Inspire Medical Systems $INSP after their highly touted Inspire V rollout turned out to be a total sleepwalking disaster. From training failures to billing chaos and low demand, the company painted a glowing picture while reality burned. Perfect for investors, analysts, and anyone tracking medtech risks. Expect sharp breakdowns, legal insight, and cautionary tales.

    Visit ZLK.com for more info.

    Add our WhatsApp Channel.

    We’re not lawyers or accountants, so don’t take this as legal or financial advice.

    8 min
  • #062 $KMX Misfires How CarMax’s “Tariff Turbo” Turned into a Legal Tailspin

    In this episode, we dig into the class action lawsuit against CarMax $KMX after a 20 percent stock nosedive. Did execs hype their financials during a short-lived buying boom fueled by tariff rumors? Investors say yes and the legal fallout could shake up how companies spin short-term wins. Ideal for retail traders, shareholders, and finance buffs. Expect sharp banter, legal insights, and Wall Street accountability.

    Visit ZLK.com for more info.

    Add our WhatsApp Channel.

    We’re not lawyers or accountants, so don’t take this as legal or financial advice.

    8 min

About SueWallSt

From the publisher's feed

Sue Wall Street digs into the scams, cover-ups, and corporate faceplants that Wall Street hopes you’ll ignore. From fraud and insider trading to the whistleblowers who called it out we break down how…